Physician profile
Hannah Dignan
NPI 1144789264
$990.12
in general payments reported to CMS, 2019-2025
13 companies · $75.93 in 2025
The $75.93 reported for 2025 was less than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $246 · 2022: $164 · 2023: $298 · 2024: $207 · 2025: $75.93.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $581.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $580.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $158.52 | 2023 | Trodelvy |
| Merck Sharp & Dohme LLC | $141.98 | 2023-2024 | Keytruda, Lenvima, Lynparza |
| G1 Therapeutics, INC. | $111.52 | 2022 | |
| Abbvie INC. | $108.25 | 2021-2024 | |
| Astrazeneca Pharmaceuticals LP | $97.91 | 2022-2024 | Enhertu, Lynparza |
| Seagen INC. | $94.51 | 2021 | |
| Amgen INC. | $75.93 | 2025 | Repatha |
| Novocure INC. | $64.15 | 2021 | |
| Eisai INC. | $58.27 | 2023-2024 | |
| Daiichi Sankyo INC. | $26.88 | 2023 | Enhertu |
| Novartis Pharmaceuticals Corporation | $22.49 | 2023 | |
| Janssen Biotech, INC. | $16.25 | 2023 | Imbruvica |
| Pfizer INC. | $13.46 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hannah Dignan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.